Psyence Biomedical Ltd. Common Shares
PBMPsyence Biomedical Ltd. (PBM) is a life sciences company focused on researching, developing, and commercializing medical and wellness products based on psychedelic and plant-based compounds. The company aims to advance mental health treatments and promote wellness through innovative therapies and formulations, leveraging scientific expertise and emerging regulatory frameworks in the field of psychedelics.
Company News
Psyence Biomedical Ltd. (Nasdaq: PBM) announced the adjournment of its annual and special shareholder meeting originally scheduled for January 22, 2026, to February 12, 2026, due to failure to achieve the requisite quorum. The company is working with proxy agents to ensure sufficient shareholder participation at the rescheduled meeting.
Psyence BioMed advanced its Phase IIb clinical trial for psilocybin-assisted psychotherapy in palliative care, secured nature-derived psilocybin and ibogaine supply, and positioned itself as a leader in longevity science research.
Psyence BioMed made a $3.5 million follow-on investment in PsyLabs, a leading producer of psychedelic pharmaceutical ingredients, to secure a sustainable and ethical supply chain for its clinical research programs in mental health therapies.
U.S. stock futures declined ahead of the 'Triple Witching' hour, with the market expected to see the expiry of about $6.6 trillion options. Analysts have mixed views on the market's recovery by the end of the year.
Psyence Biomedical has acquired an 11.13% stake in PsyLabs, a company focused on the cultivation and production of psychedelic active pharmaceutical ingredients. The acquisition is expected to benefit Psyence Biomedical's pipeline of psychedelic-based therapeutics.